|
PUT
|
$4.3 Million
|
87.6K
|
Q2 2025
Added 22.01%
|
|
Catalyst Pharmaceuticals Inc
|
CALL
|
$101,000
|
4.7K
|
Q2 2025
Reduced 67.59%
|
|
Catalyst Pharmaceuticals Inc
|
PUT
|
$173,000
|
8K
|
Q2 2025
Added 400.0%
|
|
|
CALL
|
$199,000
|
9.3K
|
Q2 2025
Added 10.71%
|
|
|
PUT
|
$189,000
|
8.8K
|
Q2 2025
Reduced 14.56%
|
|
|
CALL
|
$0
|
100
|
Q2 2025
Reduced 80.0%
|
|
|
CALL
|
$56,000
|
500
|
Q2 2025
New holding
|
|
|
PUT
|
$112,000
|
1K
|
Q2 2025
Reduced 76.19%
|
|
Cheniere Energy Partners LP
|
CALL
|
$61,000
|
1.1K
|
Q2 2025
Reduced 69.44%
|
|
Cheniere Energy Partners LP
|
PUT
|
$123,000
|
2.2K
|
Q2 2025
Reduced 45.0%
|
|
|
CALL
|
$132,000
|
700
|
Q2 2025
Reduced 95.24%
|
|
|
CALL
|
$2.06 Million
|
57.9K
|
Q2 2025
Added 6.04%
|
|
|
PUT
|
$1.08 Million
|
30.5K
|
Q2 2025
Reduced 66.07%
|
|
Corbus Pharmaceuticals Hldgs
|
CALL
|
$1,000
|
200
|
Q1 2025
Reduced 96.3%
|
|
Corbus Pharmaceuticals Hldgs
|
PUT
|
$0
|
100
|
Q2 2025
Reduced 91.67%
|
|
|
CALL
|
$118,000
|
93.8K
|
Q2 2025
Reduced 18.01%
|
|
|
PUT
|
$0
|
400
|
Q2 2025
Reduced 97.37%
|
|
|
CALL
|
$118,000
|
2.6K
|
Q2 2025
Reduced 76.79%
|
|
|
CALL
|
$16,000
|
2.5K
|
Q2 2025
Added 78.57%
|
|
|
PUT
|
$8,000
|
1.3K
|
Q2 2025
New holding
|
|
|
CALL
|
$414,000
|
132K
|
Q2 2025
Added 718.01%
|
|
|
PUT
|
$226,000
|
71.9K
|
Q2 2025
Added 184.19%
|
|
|
CALL
|
$107,000
|
79K
|
Q2 2025
Reduced 35.67%
|
|
|
CALL
|
$186,000
|
17.3K
|
Q2 2025
Reduced 11.28%
|
|
|
PUT
|
$393,000
|
36.6K
|
Q2 2025
Added 4.57%
|
|
|
CALL
|
$35,000
|
8.6K
|
Q2 2025
Added 6.17%
|
|
|
PUT
|
$8,000
|
2K
|
Q2 2025
Reduced 71.43%
|
|
|
CALL
|
$281,000
|
32.7K
|
Q2 2025
Reduced 2.68%
|
|
|
PUT
|
$575,000
|
66.9K
|
Q2 2025
Added 8.6%
|
|
|
CALL
|
$2.39 Million
|
26K
|
Q2 2025
Reduced 79.5%
|
|
|
PUT
|
$1 Million
|
10.9K
|
Q2 2025
Reduced 23.24%
|
|
|
CALL
|
$2.3 Million
|
76.3K
|
Q2 2025
Added 1111.11%
|
|
|
PUT
|
$42,000
|
1.4K
|
Q2 2025
Reduced 65.0%
|
|
|
CALL
|
$4.62 Million
|
167K
|
Q2 2025
Reduced 44.01%
|
|
Charles Riv Labs Intl Inc
|
CALL
|
$1.14 Million
|
7.5K
|
Q2 2025
Added 92.31%
|
|
Charles Riv Labs Intl Inc
|
PUT
|
$1.82 Million
|
12K
|
Q2 2025
Added 57.89%
|
|
|
CALL
|
$1.4 Million
|
114K
|
Q2 2025
Reduced 46.69%
|
|
|
PUT
|
$290,000
|
23.6K
|
Q2 2025
Reduced 66.71%
|
|
|
CALL
|
$799,000
|
78.3K
|
Q2 2025
Reduced 14.89%
|
|
|
PUT
|
$858,000
|
84.1K
|
Q2 2025
Added 68.54%
|
|
|
CALL
|
$10,000
|
4.2K
|
Q2 2025
Reduced 57.14%
|
|
|
PUT
|
$444,000
|
181K
|
Q2 2025
Added 183.67%
|
|
Crinetics Pharmaceuticals In
|
CALL
|
$23,000
|
800
|
Q1 2025
Reduced 88.24%
|
|
Crinetics Pharmaceuticals In
|
PUT
|
$5,000
|
200
|
Q2 2025
Reduced 50.0%
|
|
|
CALL
|
$592,000
|
310K
|
Q2 2025
Reduced 36.11%
|
|
|
PUT
|
$402,000
|
211K
|
Q2 2025
Reduced 58.15%
|
|
|
CALL
|
$4.71 Million
|
46.5K
|
Q2 2025
Reduced 15.3%
|
|
|
PUT
|
$7.97 Million
|
78.7K
|
Q2 2025
Reduced 16.54%
|
|
First Tr Exchng Traded Fd Vi
|
CALL
|
$9,000
|
500
|
Q2 2025
Reduced 83.33%
|
|
First Tr Exchng Traded Fd Vi
|
PUT
|
$38,000
|
1.9K
|
Q2 2025
Added 375.0%
|
|